COVID-19: Prevention & Investigational Treatments
Other names: 2019 Novel Coronavirus; 2019-nCoV; Coronavirus; Novel Coronavirus Pneumonia; SARS-CoV-2 Infection
See also: sub-topics
Drugs used to treat COVID-19
The following list of medications are in some way related to or used in the treatment of this condition.
Drug name | Rating | Reviews | Activity ? | Rx/OTC | Pregnancy | CSA | Alcohol |
---|---|---|---|---|---|---|---|
ivermectin Off-label | 8.0 | 19 reviews | Rx | ||||
Generic name: ivermectin systemic Drug class: anthelmintics For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information Off-label: Yes |
|||||||
Paxlovid EUA | 6.6 | 340 reviews | Rx | ||||
Generic name: nirmatrelvir / ritonavir systemic Drug class: antiviral combinations For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
remdesivir | 5.2 | 36 reviews | Rx | ||||
Generic name: remdesivir systemic Brand name: Veklury Drug class: purine nucleosides For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Olumiant | 1.0 | 2 reviews | Rx | ||||
Generic name: baricitinib systemic Drug class: antirheumatics, selective immunosuppressants For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
Pfizer-BioNTech COVID-19 Vaccine | 7.0 | 13 reviews | Rx | ||||
Generic name: sars-cov-2 mrna (tozinameran) vaccine Drug class: viral vaccines For consumers: dosage, interactions, side effects |
|||||||
Moderna COVID-19 Vaccine EUA | 5.0 | 30 reviews | Rx | ||||
Generic name: sars-cov-2 (covid-19) mrna-1273 vaccine systemic Drug class: viral vaccines For consumers: dosage, interactions, side effects |
|||||||
Veklury | Rate | Add review | Rx | ||||
Generic name: remdesivir systemic Drug class: purine nucleosides For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
molnupiravir EUA | 5.9 | 15 reviews | Rx | ||||
Generic name: molnupiravir systemic Brand name: Lagevrio Drug class: miscellaneous antivirals For consumers: dosage, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Lagevrio EUA | 10 | 1 review | Rx | ||||
Generic name: molnupiravir systemic Drug class: miscellaneous antivirals For consumers: dosage, side effects |
|||||||
Janssen COVID-19 Vaccine EUA | 5.4 | 5 reviews | Rx | ||||
Generic name: sars-cov-2 (covid-19) ad26 vaccine, recombinant systemic Drug class: viral vaccines For consumers: dosage, interactions, side effects |
|||||||
bamlanivimab / etesevimab EUA | 1.0 | 1 review | Rx | ||||
Generic name: bamlanivimab / etesevimab systemic Brand name: bamlanivimab and etesevimab For consumers: For professionals: Prescribing Information |
|||||||
REGEN-COV | 5.5 | 2 reviews | Rx | ||||
Generic name: casirivimab / imdevimab systemic Drug class: antiviral combinations For consumers: dosage, interactions, For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
sotrovimab EUA | Rate | Add review | Rx | ||||
Generic name: sotrovimab systemic Drug class: miscellaneous antivirals For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
nirmatrelvir / ritonavir EUA | 6.7 | 344 reviews | Rx | ||||
Generic name: nirmatrelvir / ritonavir systemic Brand name: Paxlovid Drug class: antiviral combinations For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
sars-cov-2 (covid-19) ad26 vaccine, recombinant EUA | 5.4 | 5 reviews | Rx | ||||
Generic name: sars-cov-2 (covid-19) ad26 vaccine, recombinant systemic Brand name: Janssen COVID-19 Vaccine Drug class: viral vaccines For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
sars-cov-2 mrna (tozinameran) vaccine | 7.0 | 13 reviews | Rx | ||||
Generic name: sars-cov-2 mrna (tozinameran) vaccine Brand names: Pfizer-BioNTech COVID-19 Vaccine, Comirnaty Drug class: viral vaccines For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Actemra | Rate | Add review | Rx | ||||
Generic name: tocilizumab systemic Drug class: interleukin inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
bamlanivimab and etesevimab EUA | 1.0 | 1 review | Rx | ||||
Generic name: bamlanivimab / etesevimab systemic For consumers: For professionals: AHFS DI Monograph |
|||||||
Comirnaty | Rate | Add review | Rx | ||||
Generic name: sars-cov-2 mrna (tozinameran) vaccine Drug class: viral vaccines For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
sars-cov-2 (covid-19) mrna-1273 vaccine EUA | 5.0 | 30 reviews | Rx | ||||
Generic name: sars-cov-2 (covid-19) mrna-1273 vaccine systemic Brand names: Moderna COVID-19 Vaccine, Spikevax Drug class: viral vaccines For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
tocilizumab | Rate | Add review | Rx | ||||
Generic name: tocilizumab systemic Brand name: Actemra Drug class: interleukin inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
anakinra EUA | Rate | Add review | Rx | ||||
Generic name: anakinra systemic Brand name: Kineret Drug class: antirheumatics, interleukin inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
baricitinib | 1.0 | 2 reviews | Rx | ||||
Generic name: baricitinib systemic Brand name: Olumiant Drug class: antirheumatics, selective immunosuppressants For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
bebtelovimab Off-label | 3.5 | 4 reviews | Rx | ||||
Generic name: bebtelovimab systemic Drug class: miscellaneous antivirals For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information Off-label: Yes |
|||||||
Kineret EUA | Rate | Add review | Rx | ||||
Generic name: anakinra systemic Drug class: antirheumatics, interleukin inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
Frequently asked questions
- Can you have Covid without a fever?
- What temperature is considered a fever?
- Which breathing techniques help with COVID-19?
- Is Omicron worse than Delta?
- How effective is Lagevrio (molnupiravir) for COVID-19?
- Can you become immune to COVID-19?
- Is obesity a major risk factor for Covid-19?
Topics under COVID-19
- Post-Exposure Prophylaxis of COVID-19 (3 drugs)
- Pre-Exposure Prophylaxis of COVID-19 (1 drug)
Learn more about COVID-19
Care guides
Medicine.com guides (external)
Legend
Rating | For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |
---|---|
Activity | Activity is based on recent site visitor activity relative to other medications in the list. |
Rx | Prescription only. |
OTC | Over-the-counter. |
Rx/OTC | Prescription or Over-the-counter. |
Off-label | This medication may not be approved by the FDA for the treatment of this condition. |
EUA | An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives. |
Expanded Access | Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. |
Pregnancy Category | |
---|---|
A | Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). |
B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. |
C | Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
X | Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits. |
N | FDA has not classified the drug. |
Controlled Substances Act (CSA) Schedule | |
---|---|
M | The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication. |
U | CSA Schedule is unknown. |
N | Is not subject to the Controlled Substances Act. |
1 | Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision. |
2 | Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence. |
3 | Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
4 | Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
5 | Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Alcohol | |
---|---|
X | Interacts with Alcohol. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.